Schistosomiasis Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 70.42 Million |
| Market Size (2029) | USD 84.28 Million |
| CAGR (2024 - 2029) | 3.66 % |
| Fastest Growing Market | Middle East and Africa |
| Largest Market | Asia Pacific |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Schistosomiasis Treatment Market Analysis
The Schistosomiasis-treatment-market is expected to grow from USD 70.42 million in 2024 to USD 84.28 million by 2029, at a CAGR of 3.66% during the forecast period (2024-2029).
The major factors driving market growth include the high burden of schistosomiasis, limited access to clean water in developing countries, and the surging government initiatives to eradicate the parasitic infection.
According to the Key Facts updated by the World Health Organization in April 2024, schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma. The organization also reported that approximately 251.4 million people required preventive treatment for the condition.
The limited access to clean water in certain regions is also a significant factor for the high prevalence of the disease. For instance, as per the abovementioned source, schistosomiasis affects almost 240 million people worldwide, and more than 700 million people live in endemic areas. Tropical and subtropical regions and underdeveloped communities lacking access to potable water and proper sanitation are more prone to infection. In addition, as per the article published by the Centers for Disease Control and Prevention in May 2023, approximately 85% of global cases of schistosomiasis are found in Africa, where prevalence rates can surpass 50% in local populations.
The increasing number of government and private companies' initiatives are also expected to propel the growth of the schistosomiasis treatment market. For instance, in December 2022, Merck KGaA and the Pediatric Praziquantel Consortium announced that the European Medicines Agency (EMA) had validated for review the application for Arpraziquantel for the treatment of schistosomiasis in preschool-aged children. In January 2022, Merck KGaA also provided over 1.5 billion praziquantel tablets in partnership with WHO to Sub-Saharan Africa.
Therefore, the high prevalence of schistosomiasis, limited access to clean water, and increasing government initiatives drive advancements and investment in treatment solutions globally. However, stringent regulatory approvals are restraining the growth of the schistosomiasis treatment market.
Schistosomiasis Treatment Market Trends
The Urogenital Segment is Expected to Record Significant Growth During the Forecast Period
Urogenital Schistosomiasis is a specific form of schistosomiasis caused by the parasitic worm Schistosoma haematobium. It is also known as urinary schistosomiasis because it primarily affects the urinary system, including the bladder, ureters, and urinary tract. The major factors driving the segment’s growth include high disease burden, lack of access to clean water and sanitation, increasing health awareness and education, and various initiatives taken by government and non-government organizations to eradicate the disease.
For instance, according to the research article published by the PLOS One Journal in July 2022, Urogenital Schistosomiasis, caused by Schistosoma haematobium is highly distributed throughout Africa and the Middle East. According to the same source, among individuals infected with S. haematobium, around 70 million experienced haematuria (blood in urine), 32 million dysuria (painful urination), 18 million bladder-wall pathologies, and 10 million significant hydronephroses within two weeks of infection in Sub-Saharan Africa. Urogenital schistosomiasis also causes nutritional deficiency, poor cognitive development, growth retardation, and a decrease in productivity and work capacity. Therefore, significant risk factors associated with urogenital schistosomiasis are projected to drive the segment’s growth during the forecast period.
Various government initiatives to eradicate urogenital schistosomiasis are also projected to drive market growth during the forecast period. For instance, in March 2023, a Female Genital Schistosomiasis Society of Nigeria (FGSSoN) was officially launched to eliminate female genital schistosomiasis (FGS) and other related infectious diseases in Nigeria and globally. The Society is well networked across the six geopolitical zones and 36 states of Nigeria, including the Federal Capital Territory (FCT).
Therefore, the combination of high disease burden, inadequate access to clean water and sanitation, increased health awareness, and governmental initiatives are expected to accelerate the growth of the segment significantly.
Middle East and Africa is Expected to Hold a Significant Market Share Over the Forecast Period
Middle East and Africa hold a significant share of the market. This is due to the high prevalence of schistosomiasis, increasing government initiatives and healthcare programs, increasing awareness, and rising investments in the healthcare sector in the region. For instance, as per an article published by Medscape in March 2023, over 140 million people, 90% from Africa, had schistosomiasis. Therefore, the region's high disease burden is projected to boost market growth during the forecast period.
According to an article published by the Taylor & Francis Journal in January 2023, schistosomiasis was one of the top ten causes of hospital admissions in Zimbabwe. The general population prevalence was 22.7%. According to the same source, urogenital schistosomiasis was one of the most devastating tropical diseases in the world, causing significant morbidity and mortality in developing countries such as Africa.
Governments and healthcare organizations in Middle East and Africa recognize the importance of addressing neglected tropical diseases like schistosomiasis. They have been implementing various initiatives and programs to improve diagnosis, treatment, and prevention of the disease. These efforts drive the demand for schistosomiasis treatment. In February 2022, WHO launched a new guideline for controlling and eliminating human schistosomiasis in Middle East and Africa. The main aim of WHO is to eradicate schistosomiasis as a public health problem and to interrupt the transmission of schistosomiasis in humans in MEA by 2030.
The regional market is expected to witness significant growth during the forecast period due to the high prevalence of schistosomiasis, increasing government initiatives, and healthcare programs.
Schistosomiasis Treatment Industry Overview
The schistosomiasis treatment market is consolidated due to a limited number of companies that manufacture and distribute schistosomiasis drugs. The competitive landscape includes an analysis of several international and local companies that hold market shares and are well known, including Merck KGaA, Bayer AG, and EIPICO.
Schistosomiasis Treatment Market Leaders
-
Merck KGaA
-
Bayer AG
-
Salvensis
-
GlaxoSmithKline PLC
-
Egyptian International Pharmaceutical Industries Company
*Disclaimer: Major Players sorted in no particular order
Schistosomiasis Treatment Market News
- March 2024: The American Society for Biochemistry and Molecular Biology developed a compound that showed promise in animal studies as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms.
- February 2024: The European Medicines Agency adopted a positive scientific opinion of Arpraziquantel (a child-friendly praziquantel formulation by the Pediatric Praziquantel Consortium).
Schistosomiasis Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Burden of Schistosomiasis and Limited Access to Clean Water in Developing Countries
4.2.2 Surging Government Initiatives
4.3 Market Restraints
4.3.1 Stringent Regulatory Approvals
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value-USD)
5.1 By Site of Infection
5.1.1 Intestinal
5.1.2 Urogenital
5.1.3 Hepatosplenic
5.2 By Species Type
5.2.1 Schistosoma mansoni
5.2.2 Schistosoma japonicum
5.2.3 Others
5.3 By Drug Type
5.3.1 Praziquantel
5.3.2 Metrifonate
5.3.3 Oxamniquine
5.3.4 Others
5.4 By End User
5.4.1 Hospitals
5.4.2 Homecare
5.4.3 Specialty Centers
5.4.4 Others
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck KGaA
6.1.2 Bayer AG
6.1.3 Egyptian International Pharmaceutical Industries Company
6.1.4 GlaxoSmithKline
6.1.5 Taj Pharmaceuticals Limited
6.1.6 Endo International (Par Pharmaceutical Holdings)
6.1.7 Salvensis
6.1.8 Wellona Pharma
6.1.9 Weefsel Pharma
6.1.10 CBC Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Schistosomiasis Treatment Industry Segmentation
Schistosomiasis treatment involves the use of medications, like praziquantel, to kill the parasitic worms (schistosomes) that cause the disease. The treatment aims to eliminate or reduce the number of schistosomes in the body, to relieve symptoms, to prevent complications, and to reduce transmission.
The schistosomiasis treatment market is segmented by site of infection, species type, drug type, end user, and geography. By site of infection, the market is further segmented into the intestinal, urogenital, and hepatosplenic. The species type segment is further segmented into Schistosoma mansoni, Schistosoma japonicum, and others. The drug type segment is further segmented into praziquantel, metrifonate, biltricide, oxamniquine, and others. The end-user segment is segmented into hospitals, home care, and specialty centers. The geography segment is further segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for all the above segments.
| By Site of Infection | |
| Intestinal | |
| Urogenital | |
| Hepatosplenic |
| By Species Type | |
| Schistosoma mansoni | |
| Schistosoma japonicum | |
| Others |
| By Drug Type | |
| Praziquantel | |
| Metrifonate | |
| Oxamniquine | |
| Others |
| By End User | |
| Hospitals | |
| Homecare | |
| Specialty Centers | |
| Others |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Schistosomiasis Treatment Market Research Faqs
How big is the Schistosomiasis Treatment Market?
The Schistosomiasis Treatment Market size is expected to reach USD 70.42 million in 2024 and grow at a CAGR of 3.66% to reach USD 84.28 million by 2029.
What is the current Schistosomiasis Treatment Market size?
In 2024, the Schistosomiasis Treatment Market size is expected to reach USD 70.42 million.
Who are the key players in Schistosomiasis Treatment Market?
Merck KGaA, Bayer AG, Salvensis, GlaxoSmithKline PLC and Egyptian International Pharmaceutical Industries Company are the major companies operating in the Schistosomiasis Treatment Market.
Which is the fastest growing region in Schistosomiasis Treatment Market?
Middle East and Africa is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Schistosomiasis Treatment Market?
In 2024, the Asia Pacific accounts for the largest market share in Schistosomiasis Treatment Market.
What years does this Schistosomiasis Treatment Market cover, and what was the market size in 2023?
In 2023, the Schistosomiasis Treatment Market size was estimated at USD 67.84 million. The report covers the Schistosomiasis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Schistosomiasis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Schistosomiasis Treatment Industry Report
Statistics for the 2024 Schistosomiasis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Schistosomiasis Treatment analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
